Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.
暂无分享,去创建一个
[1] E. Barrett-Connor,et al. Hormones and heart disease in women: Heart and Estrogen/Progestin Replacement Study in perspective. , 1999, The Journal of clinical endocrinology and metabolism.
[2] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.
[3] N. Wenger,et al. Coronary heart disease: an older woman's major health risk , 1997, BMJ.
[4] J. Gustafsson,et al. Estrogen receptor β acts as a dominant regulator of estrogen signaling , 2000, Oncogene.
[5] Lynda H. Powell. Breast cancer and hormone-replacement therapy. , 1995, The New England journal of medicine.
[6] D. Wickerham,et al. Breast cancer chemoprevention: current status and future directions. , 2001, Seminars in oncology.
[7] R B Mazess,et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.
[8] Susan R. Johnson,et al. Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .
[9] D. McDonnell,et al. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. , 1999, Endocrinology.
[10] P. Goss,et al. Aromatase inhibitors in the treatment and prevention of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Helterbrand,et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. , 2001, The American journal of cardiology.
[12] J. Carson,et al. Risk of venous thromboembolism in users of hormone replacement therapy , 1996, The Lancet.
[13] C. Cotman,et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. , 2000, JAMA.
[14] V. Jordan,et al. Selective estrogen receptor modulation: a personal perspective. , 2001, Cancer research.
[15] B. Riggs,et al. Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized Trial , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[16] Robert Selzer,et al. Estrogen in the Prevention of Atherosclerosis , 2001, Annals of Internal Medicine.
[17] Brenda L Plassman,et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. , 2002, JAMA.
[18] J. Gustafsson,et al. Estrogen receptor beta--a new dimension in estrogen mechanism of action. , 1999, The Journal of endocrinology.
[19] Kristen Jepsen,et al. Combinatorial Roles of the Nuclear Receptor Corepressor in Transcription and Development , 2000, Cell.
[20] C. Christiansen,et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.
[21] Raloxifene, an oestrogen-receptor modulator, prevents decreased constitutive nitric oxide and vasoconstriction in ovariectomized rats. , 2000, European journal of pharmacology.
[22] A. LaCroix,et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.
[23] Anthony Gamst,et al. Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial , 2000 .
[24] R. Recker,et al. Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis , 1996 .
[25] L. Melton,et al. Role of Low Levels of Endogenous Estrogen in Regulation of Bone Resorption in Late Postmenopausal Women , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[26] K. Kerlikowske,et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. , 1995, Obstetrics and gynecology.
[27] G. Hortobagyi,et al. Update on endocrine therapy for breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] J. Cuzick,et al. Chemoprevention of breast cancer with tamoxifen. , 1996, IARC scientific publications.
[29] J. Reginster,et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. , 2000, The Journal of clinical endocrinology and metabolism.
[30] Sundeep Khosla,et al. Sex steroids and the construction and conservation of the adult skeleton. , 2002, Endocrine reviews.
[31] Zbigniew Dauter,et al. Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.
[32] S. Cummings,et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] S. Lundgren,et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study. , 1997, British Journal of Cancer.
[34] James N Ingle,et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] C. Hudis,et al. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] R. Legare,et al. Adjuvant therapy in breast cancer. , 2002, Obstetrics and gynecology clinics of North America.
[37] E. Winer,et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] M. Hooper,et al. Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.
[39] A. Howell,et al. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer , 1997, International journal of cancer.
[40] C. Schneeberger,et al. Production and actions of estrogens. , 2002, The New England journal of medicine.
[41] K. Dahlman-Wright,et al. Estrogen Receptor (ER)-β Reduces ERα-Regulated Gene Transcription, Supporting a “Ying Yang” Relationship between ERα and ERβ in Mice , 2003 .
[42] M Carlquist,et al. Structural insights into the mode of action of a pure antiestrogen. , 2001, Structure.
[43] C. Christiansen,et al. Raloxifene and estrogen reduces progression of advanced atherosclerosis--a study in ovariectomized, cholesterol-fed rabbits. , 2001, Atherosclerosis.
[44] S. Azen,et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. , 2001, Annals of internal medicine.
[45] L. Arrighi,et al. [Treatment of breast cancer]. , 1971, Prensa medica argentina.
[46] J. Lindgren,et al. Effects of anti-estrogens on bone in castrated and intact female rats , 1987, Breast Cancer Research and Treatment.
[47] D. Cox,et al. Raloxifene and estrogen inhibit neointimal thickening after balloon injury in the carotid artery of male and ovariectomized female rats. , 2000, Journal of cardiovascular pharmacology.
[48] Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. , 1994, Archives of internal medicine.
[49] D. Reboussin,et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. , 2000, The New England journal of medicine.
[50] D. Hayes,et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] S. Legha,et al. Tamoxifen in the treatment of breast cancer. , 1988, Annals of internal medicine.
[52] I. Reid,et al. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. , 1995, The American journal of medicine.
[53] T. Powles,et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] P. Goss,et al. Estrogen and the risk of breast cancer. , 2001, The New England journal of medicine.
[55] A. Buzdar,et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] David A. Agard,et al. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.
[57] R. Turner,et al. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. , 1988, Endocrinology.
[58] S. Paul,et al. Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats , 1999, Brain Research.
[59] Harry K. Genant,et al. Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .
[60] B. O’Malley,et al. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.
[61] Myles Brown,et al. Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.
[62] K. Grandien,et al. Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .
[63] J. Garland. The New England Journal of Medicine. , 1961, Canadian Medical Association journal.
[64] J. Bryant,et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. , 2001, Journal of the National Cancer Institute.
[65] K. Korach,et al. Estrogen receptor null mice: what have we learned and where will they lead us? , 1999, Endocrine reviews.
[66] T. Powles,et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.
[67] David Greenblatt,et al. Treatment of Postmenopausal Osteoporosis , 2005, Pharmacotherapy.
[68] S. Cummings,et al. The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial , 2000 .
[69] P. Boyle,et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.
[70] R. Gray,et al. The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: randomize into aTTom. , 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).
[71] B. McEwen,et al. Estrogen actions in the central nervous system. , 1999, Endocrine reviews.
[72] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[73] L. Kuller,et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. , 1998, JAMA.
[74] M. Anthony,et al. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. , 1998, The Journal of clinical endocrinology and metabolism.
[75] J. Satagopan,et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.
[76] E. Vittinghoff,et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.
[77] D. McDonnell,et al. The Molecular Pharmacology of SERMs , 1999, Trends in Endocrinology & Metabolism.
[78] M Baum,et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.
[79] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[80] J. Reginster,et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. , 2000, The Journal of clinical endocrinology and metabolism.
[81] T. Walsh,et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. , 2001, JAMA.
[82] E. Vittinghoff,et al. Postmenopausal Hormones and Incontinence: The Heart and Estrogen/Progestin Replacement Study , 2001, Obstetrics and gynecology.
[83] R. Lanz,et al. Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.
[84] E. Barrett-Connor,et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. , 2002, JAMA.
[85] Ose,et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .
[86] H Grøn,et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[87] Osborne Ck,et al. Tamoxifen in the Treatment of Breast Cancer , 1998 .
[88] K Yaffe,et al. Cognitive function in postmenopausal women treated with raloxifene. , 2001, The New England journal of medicine.
[89] P. Hietanen,et al. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. , 1998, The Journal of clinical endocrinology and metabolism.
[90] Paul Cleary,et al. Use of Hormone Replacement Therapy by Postmenopausal Women in the United States , 1999, Annals of Internal Medicine.
[91] J. Robertson,et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] R. Tracy,et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. , 2000, The Journal of clinical endocrinology and metabolism.
[93] M. Taskinen,et al. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[95] D. Fowlkes,et al. Peptide antagonists of the human estrogen receptor. , 1999, Science.
[96] H. Mouridsen,et al. Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen , 2005, Breast Cancer Research and Treatment.
[97] D. McDonnell,et al. The Estrogen Receptor -isoform (er) of the Human Estrogen Receptor Modulates Er␣ Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens* , 2022 .
[98] J-A,et al. Estrogen receptor (cid:1) – a new dimension in estrogen mechanism of action , 1999 .
[99] B. L. Riggs,et al. Bone Turnover Matters: The Raloxifene Treatment Paradox of Dramatic Decreases in Vertebral Fractures Without Commensurate Increases in Bone Density , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[100] D. DeMets,et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. , 1991, Annals of internal medicine.
[101] C. Christiansen,et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. , 2000, Archives of internal medicine.
[102] E. Vittinghoff,et al. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. , 2002, JAMA.
[103] E. Siris,et al. Effects of tamoxifen on spinal bone density in women with breast cancer. , 1989, Journal of the National Cancer Institute.
[104] J. Compston,et al. Estrogen Receptors α and β Are Differentially Expressed in Developing Human Bone1 , 2001 .
[105] J. Abrams. Tamoxifen: five versus ten years--is the end in sight? , 2001, Journal of the National Cancer Institute.
[106] Susan L Neuhausen,et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.